76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Tandem Diabetes Care Inc
Closed
SectorHealthcare
19.13 -1.39
Overview
Share price change
24h
Min
18.99
Max
19.46
Income | -131M -131M |
|---|---|
Sales | -48M 234M |
EPS | -0.665 |
Profit margin | -55.693 |
Employees | 2,650 |
EBITDA | -121M -116M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +94.59% upside |
Next Earnings | 31 Jul 2025 |
|---|
Market Cap | 184M 1.3B |
|---|---|
Previous open | 20.52 |
Previous close | 19.13 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Tandem Diabetes Care Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Tandem Diabetes Care Inc Forecast
Price Target
By TipRanks
94.59% upside
12 Months Forecast
Average 37.79 USD 94.59%
High 75 USD
Low 18 USD
Based on 16 Wall Street analysts offering 12 month price targets forTandem Diabetes Care Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Tandem Diabetes Care Inc
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
